Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

Please find enclosed a Press Release on

"Dr. Reddy's Laboratories announces Senior Leadership Changes".

This is for your information.

CC:- New York Stock Exchange Inc.(Stock Code: RDY)

Reddy's Laboratories announces Senior Leadership Changes

Hyderabad, India March 29, 2018-

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced a change in the makeup of its senior

Following a 15-year career with the

company, Mr. Abhijit Mukherjee, Chief Operating Officer, will retire on March 31, 2018.

Mr. Mukherjee will be succeeded by

Mr. Erez Israeli, former President & CEO of Enzymotec. Mr. Israeli will join Dr. Reddy's on April 2, 2018, as Chief Operating

Officer and Global Head of Generics & PSAI, based out of Hyderabad. He will report to Dr. Reddy's Co-Chairman & CEO,

In a career spanning over 25 years, Israeli has held leadership

positions that have contributed significantly to the performance of companies he worked for. Prior to Enzymotec, he completed 23

years with Teva Pharmaceuticals Limited, where he held several positions of responsibility including Vice President Marketing &

Sales for North America, Vice President Asia Operations, President Teva API, Group Executive Vice President, Head of Global Quality,

and President & CEO Growth Markets.

Speaking about the transition, G.V. Prasad said, "I would

like to thank Abhijit for his valuable contribution to our company's growth journey over the past fifteen years. I extend

a warm welcome to Erez Israeli. Erez is an accomplished leader with a proven track record of achievement. His knowledge and experience

from leading pharmaceutical businesses of scale will be valuable for our future growth."

About Dr. Reddy's: Dr. Reddy's Laboratories

Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative

medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics

and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical

services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular,

diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major markets

include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

Disclaimer: This press release may include

statements of future expectations and other forward-looking statements that are based on the management's current views and

assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ

materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of

context, the words "may", "will", "should", "expects", "plans", "intends",

"anticipates", "believes", "estimates", "predicts", "potential", or "continue"

and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those

in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit

defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality

and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and

regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including

related integration issues.

The company assumes no obligation to update any information